C3 International

Idrasil, a cannabis-based tablet aimed at the medical community, is at the center of a long-running lawsuit filed by the Securities and Exchange Commission against a California cannabis company. The SEC alleges fraud and investor losses in the lawsuit, filed Sept. 28, 2021 against C3 International...

Editor's note: Please click here for an April 2024 update on the SEC's lawsuit against C3 International.  C3 International, a California-based cannabis company, refused to participate in a case in which it is being accused, along with its CEO and president, of defrauding at...

Steele Clarke Smith III is chairman and CEO of C3 International, a post-proof of concept, pre-revenue life sciences company specializing in cannabinoid therapeutics. C3 achieved proof of concept in 2015. “I have been in the financial markets ever since, raising the massive amount of capital...

Two big news items dominated the cannabis industry this week: the re-scheduling of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s cannabis-derived drug, Epidiolex, from the Schedule I category to the Schedule V category; and High Times’ acquisition of Dope Magazine for $11.2 million in...